Your browser doesn't support javascript.
loading
Mass Spectrometry Imaging proves differential absorption profiles of well-characterised permeability markers along the crypt-villus axis.
Nilsson, Anna; Peric, Alexandra; Strimfors, Marie; Goodwin, Richard J A; Hayes, Martin A; Andrén, Per E; Hilgendorf, Constanze.
Affiliation
  • Nilsson A; Science for Life Laboratory, Biomolecular Imaging and Proteomics, National Resource for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
  • Peric A; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden.
  • Strimfors M; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden.
  • Goodwin RJA; Mass Spectrometry Imaging, Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca Cambridge, Cambridge, United Kingdom.
  • Hayes MA; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden.
  • Andrén PE; Science for Life Laboratory, Biomolecular Imaging and Proteomics, National Resource for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
  • Hilgendorf C; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden. Constanze.hilgendorf@astrazeneca.com.
Sci Rep ; 7(1): 6352, 2017 07 25.
Article de En | MEDLINE | ID: mdl-28743866
ABSTRACT
Knowledge about the region-specific absorption profiles from the gastrointestinal tract of orally administered drugs is a critical factor guiding dosage form selection in drug development. We have used a novel approach to study three well-characterized permeability and absorption marker drugs in the intestine. Propranolol and metoprolol (highly permeable compounds) and atenolol (low-moderate permeability compound) were orally co-administered to rats. The site of drug absorption was revealed by high spatial resolution matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) and complemented by quantitative measurement of drug concentration in tissue homogenates. MALDI-MSI identified endogenous molecular markers that illustrated the villi structures and confirmed the different absorption sites assigned to histological landmarks for the three drugs. Propranolol and metoprolol showed a rapid absorption and shorter transit distance in contrast to atenolol, which was absorbed more slowly from more distal sites. This study provides novel insights into site specific absorption for each of the compounds along the crypt-villus axis, as well as confirming a proximal-distal absorption gradient along the intestine. The combined analytical approach allowed the quantification and spatial resolution of drug distribution in the intestine and provided experimental evidence for the suggested absorption behaviour of low and highly permeable compounds.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Spectrométrie de masse MALDI / Intestins / Antihypertenseurs Type d'étude: Prognostic_studies Limites: Animals Langue: En Journal: Sci Rep Année: 2017 Type de document: Article Pays d'affiliation: Suède

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Spectrométrie de masse MALDI / Intestins / Antihypertenseurs Type d'étude: Prognostic_studies Limites: Animals Langue: En Journal: Sci Rep Année: 2017 Type de document: Article Pays d'affiliation: Suède